Daxor Pins Commercial Strategy on Value-Based Care Adoption
Event summary
- Daxor is exhibiting its Blood Volume Analyzer (BVA™) technology at the MedAxiom CV Transforum Spring’26 conference in Ponte Vedra Beach, FL, from April 30 – May 2, 2026.
- The conference is focused on cardiovascular care delivery and attracts high-level decision-makers.
- Daxor claims BVA guided care reduces 30-day mortality by 82%, 1-year mortality by 86%, and 30-day readmissions by 56%.
- CEO Michael Feldschuh stated the MedAxiom forum is a 'key component' of Daxor’s commercial strategy.
The big picture
Daxor’s strategy hinges on the broader shift towards value-based care in the US healthcare system. The company’s BVA technology is positioned to benefit from this trend, but its success depends on convincing hospitals of the technology’s economic and clinical value. The company's reliance on MedAxiom for commercial acceleration highlights the challenges of penetrating a complex and fragmented healthcare market.
What we're watching
- Adoption Rate
- The pace at which hospitals adopt Daxor’s BVA technology will be critical to its revenue projections, given the reliance on value-based reimbursement models.
- Clinical Validation
- Continued peer-reviewed validation of the BVA’s claimed mortality and readmission reductions will be essential to maintain credibility and drive wider adoption.
- Competitive Landscape
- How Daxor manages potential competitive offerings in blood volume analysis will determine its ability to maintain market share and pricing power.
Related topics